Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial

• Published in: Journal of clinical oncology Vol. 36; no. 3; pp. 231 - 237
• Main Authors: Cortes, Jorge E., Gambacorti-Passerini, Carlo, Deininger, Michael W., Mauro, Michael J., Chuah, Charles, Kim, Dong-Wook, Dyagil, Irina, Glushko, Nataliia, Milojkovic, Dragana, le Coutre, Philipp, Garcia-Gutierrez, Valentin, Reilly, Laurence, Jeynes-Ellis, Allison, Leip, Eric, Bardy-Bouxin, Nathalie, Hochhaus, Andreas, Brümmendorf, Tim H.
• Format: Journal Article
• Language: English
• Published: United States American Society of Clinical Oncology 20.01.2018
• Subjects: Adolescent; Adult; Aged; Aged, 80 and over; Aniline Compounds - adverse effects; Aniline Compounds - therapeutic use; Antineoplastic Agents - adverse effects; Antineoplastic Agents - therapeutic use; Biomarkers, Tumor - genetics; Disease Progression; Female; Fusion Proteins, bcr-abl - genetics; Genetic Predisposition to Disease; Humans; Imatinib Mesylate - adverse effects; Imatinib Mesylate - therapeutic use; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology; Male; Middle Aged; Nitriles - adverse effects; Nitriles - therapeutic use; ORIGINAL REPORTS; Phenotype; Philadelphia Chromosome; Protein Kinase Inhibitors - adverse effects; Protein Kinase Inhibitors - therapeutic use; Quinolines - adverse effects; Quinolines - therapeutic use; Time Factors; Treatment Outcome; Young Adult

Purpose Bosutinib is a potent dual SRC/ABL kinase inhibitor approved for adults with Philadelphia chromosome-positive chronic myeloid leukemia (CML) resistant and /or intolerant to prior therapy. We assessed the efficacy and safety of bosutinib versus imatinib for first-line treatment of chronic-pha...